SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is in the spotlight as investors debate the potential long-term impact of a bipartisan Senate bill aimed at banning sports-based prediction markets, which could remove a significant competitive threat to traditional sportsbooks. While some in the community see this as a pivotal win that strengthens the company's regulatory moat, others remain deeply skeptical, pointing to persistent insider selling, ongoing lawsuits, and general frustration with the stock's inability to sustain upward momentum.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense backlash and investor frustration following a 1-for-12 reverse stock split that has left many shareholders deep in the red and questioning management's long-term strategy. The community is heavily focused on the company's lack of transparent communication, stagnant performance, and the perceived abandonment of retail investors in favor of Disney's controlling stake.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over the company's heavy AI capital expenditures, the uncertain ROI of OpenAI, and a broader rotation away from software stocks. The community is deeply divided, with many debating whether the current price represents a generational buying opportunity for a fundamental giant or if the stock is broken due to perceived leadership failures and a lack of clear AI monetization.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing extreme volatility and massive upside momentum as retail investors chase exposure to high-profile private AI and space firms like SpaceX and Anthropic. While the community is debating the disconnect between the fund's net asset value and its current trading premium, bullish sentiment remains fueled by the limited float due to share lockups and anticipation of upcoming IPOs.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened investor attention following the upcoming departure of a key FDA official, which market participants view as a potential catalyst for a more predictable regulatory environment for rare disease gene therapies. The community remains heavily focused on the company's strong revenue base and upcoming clinical data readouts for its siRNA pipeline, with many investors actively debating the stock's valuation versus its growth potential.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as investors position themselves for a potential SpaceX IPO, with the stock viewed by many as a unique vehicle to gain exposure to high-growth private tech giants like SpaceX, OpenAI, and Anthropic. Community discussion remains polarized, however, as some traders highlight the stock's potential for high volatility and a potential short squeeze due to its low float, while others express caution regarding its valuation relative to its Net Asset Value (NAV) and the risks of paying a premium for closed-end fund holdings.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently the center of intense market discussion following a strategic shift to sell its own in-house AGI CPU chips for data centers, which management expects will generate billions in annual revenue by 2031. Investors and analysts are actively debating the company's valuation and the potential for a massive rerating, as the move pivots Arm from a traditional IP licensing model to a direct silicon competitor in the AI-driven data center market.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following a regulatory setback, where the FDA issued a complete response letter regarding its drug candidate relacorilant for Cushing's syndrome due to requests for additional efficacy data. While the stock has faced intense selling pressure and scrutiny over the regulatory delay and ongoing patent litigation, the community is actively debating whether the sell-off is an overreaction given the company's established, profitable Korlym franchise and the upcoming pivotal data readouts for its oncology pipeline.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is facing intense volatility as investors debate the merit of a critical short report alleging aggressive accounting practices, while the company maintains its long-term growth narrative. The community remains deeply divided, with many long-term shareholders aggressively buying the dip on conviction that the allegations are unfounded, while others remain cautious due to management's muted initial response and the stock's significant price decline.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Investors are shifting focus from animal-themed meme coins toward sea-creature narratives, fueling community excitement around the low market capitalization potential of Orcasm. Discussions center on rallying collective momentum to establish the project as a market leader while coordinating cross-token support across the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck & Co., Inc. (NYSE:MRK) Shares Acquired Rep. Josh Gottheimer

Representative Josh Gottheimer (Democratic-New Jersey) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on March 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on February 4th. The trade occurred in the Repre...

<ul class="summary-bullets"><li>The acquisition centers on Terns’ oral CML treatment, TERN-701, currently in mid-stage clinical trials.</li><li>TERN-701 received orphan drug designation in 2024, highlighting its potential for the treatment of rare leukemias.</li><li>The deal is expected to be completed in the second quarter of 2026.</li></ul>Merck &amp; Co. Inc. (MRK) has struck a multibillion-dollar deal to expand its oncology pipeline, agreeing to acquire clinical-stage biotech firm Terns Pharmaceuticals Inc. (TERN) for $53 per share in cash, at an approximate $6.7 billion valuation.&nbsp;The offer represents a 6% premium over Terns’ closing price as of Tuesday.&nbsp;<h2 class="st-heading-2">Focus On Cancer Drug Development</h2>Central to the acquisition is Terns’ experimental therapy, TERN-701, an oral treatment targeting specific mutations linked to chronic myeloid leukemia. The drug candidate is currently under evaluation in mid-stage clinical trials.&nbsp;<blockquote>“The acquisition of Terns builds on our growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia.”-Robert M. Davis, Chairman and CEO, Merck</blockquote>Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/TERN">Terns Pharmaceuticals’ stock</a> traded over 4% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Regulatory Momentum And Trial Outcomes</h2>U.S. regulators granted TERN-701 orphan drug status in 2024, signaling its potential as a treatment for a rare form of leukemia. Early trial findings have shown encouraging outcomes, including meaningful molecular responses within months of treatment.“Based on early clinical evidence, TERN-701, a novel allosteric BCR::ABL1 inhibitor, may have the potential to provide a meaningfully differentiated option for certain patients living with CML,” said Dean Y. Li, President, Merck Research Laboratories.The companies anticipate finalizing the acquisition deal in the second quarter of 2026.MRK stock has gained over 10% year to date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sandisk-commits-1-b-to-nanya-in-strategic-chip-sector-bet/cZ3YNwZRISI">Sandisk Commits $1B To Nanya In Strategic Chip Sector Bet</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Terns In $6.7B Deal – Signaling Fresh Push In Competitive Cancer Drug Race 

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.

Equity

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.


Pensionfund Sabic Makes New $3.05 Million Investment in Merck & Co., Inc. $MRK

Pensionfund Sabic purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange...

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (Terns) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies...

SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff

SLS vs TERN Stock - Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

E. Ohman J or Asset Management AB Purchases Shares of 88,457 Merck & Co., Inc. $MRK

E. Ohman J or Asset Management AB acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the...

Contravisory Investment Management Inc. Purchases 70,550 Shares of Merck & Co., Inc. $MRK

Contravisory Investment Management Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 19,435.3% in the fourth quarter, according to the company in its most recent...

Central Bank & Trust Co. Sells 13,216 Shares of Merck & Co., Inc. $MRK

Central Bank & Trust Co. decreased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 31.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,470 shares of the compa...

Avanza Fonder AB Purchases 25,344 Shares of Merck & Co., Inc. $MRK

Avanza Fonder AB increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,720 shares of the company's stock after buying an addit...

Merck (MRK) Exceeds Market Returns: Some Facts to Consider

Merck (MRK) reached $115.68 at the closing of the latest trading day, reflecting a +1.31% change compared to its last close.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Current Price	$119.70
Prev Close	$116.37
Open	$116.00
Dividend Yield	3.12%
50-Day Moving Average	$115.86
Beta	0.31
Avg. Volume	13.61M
PE Ratio	16.00

52-Week High	$125.14
52-Week Low	$73.31
Market Capitalization	$287.71B
EPS (Annual)	$7.28
Price to Book	5.47
Revenue Per Employee	$865,680.00

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc